Fourth time's the charm? blue­bird picks up new fi­nance chief; New CEOs here and there

blue­bird bio has been able to cinch two FDA OKs, one for Zyn­te­glo and the oth­er for Skysona, in quick suc­ces­sion, but has had trou­ble hold­ing on­to a CFO. In steps Chris Krawtschuk, who’ll pick up where Ja­son Cole left off as he hit the ex­it. Krawtschuk’s been CFO at Ju­bi­lant Phar­ma and Mor­phoSys and was VP, lead di­vi­sion­al con­troller at Pfiz­er. Krawtschuk marks the com­pa­ny’s third CFO just this year — af­ter Cole took over for Gi­na Con­syl­man, who left for Vedere Bio II — and is left to help steer the com­pa­ny as it be­gins sales of its near­ly $3 mil­lion gene ther­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.